TrialA Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
Trial details
- Registry ID
- NCT05066230
- Phase
- Phase 3
Drug research
Sham injection
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity has not yet been verified against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)NCT05066230 | KOD | Phase 3 | Terminated | 2023-08-03Actual |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)NCT06270836 | KOD | Phase 3 | Completed | 2026-02-13Actual |
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Trial details
- Registry ID
- NCT06270836
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |